Smith RM, Morgan A, Wraith DC. 1994 Anti-class II MHC antibodies prevent
and treat EAE without APC depletion. Immunology. 83:1-8.
Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. 1995 Low
avidity recognition of self-antigen by T cells permits escape from central
tolerance. Immunity. 3:407-15.
Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann
H, Lachmann PJ, Compston A. 1996 Mechanism of first dose cytokine release
syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and
CD11a/CD18 (LFA-1) on NK cells J Clin Invest 98: 2819-26
Smith RM, Chen ZK, Foulkes R, Metcalfe SM, Wraith DC 1997 Prolongation
of murine vascularised heart allograft survival by recipient specific anti-major
histocompatibility complex class II antibody Transplantation 64: 525-8
Smith RM & Mandel TE 1998 Transplantation treatment for diabetes
Immunology Today 19: 444-7
Saxton NE, Hallaway RV, Ladyman H, Janczynski BT, Nesbitt AM, ZinkewichPeotti K, Smith R, Foulkes R. 1999 Anti-major histocompatibility complex
class II treatment prevents graft rejection in the hamster-to-rat cardiac
xenograft model Transplantation 67: 1599-606
Wood NAP, Thomson SC, Smith RM & Bidwell JL 2000 Identification of
human TGF-b1 signal (leader) sequence polymorphisms by PCR-RFLP
Journal of Immunological Methods 234: 117-22
Smith RM & Mandel TE 2000 Pancreatic islet xenotransplantation: the
potential for tolerance induction Immunology Today 21: 42-8
Smith RM 2000 Antibodies for inflammatory disease: effector cells. In
“Diagnostic and Therapeutic Antibodies”, Humana Press Inc, eds George, A.
& Urch, C.
Youssef A-R, Otley C, Mathieson PW & Smith RM 2002 Effector mechanisms
in allograft rejection: Comparison of murine skin and heart grafts in fully
allogeneic and minor histocompatibility antigen mismatched strain
combinations. Transplant International 15:302-9
Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt
GS, Rajotte RV, Smith R, Rutter GA. 2004 Metformin, but not leptin,
regulates AMP-activated protein kinase in pancreatic islets: impact on
glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 286:
E1023-31
Smith RM 2004 CMV prophylaxis: a useful step towards prevention of posttransplant diabetes ? Diabetologia 47: 1473-5
Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt
GS, Rajotte RV, Smith R, Rutter GA. 2004 Metformin, but not leptin,
regulates AMP-activated protein kinase in pancreatic islets: impact on
glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 286:
E1023-31
Youssef A-R, Otley C, Mathieson PW & Smith RM 2004 Role of CD4+ and
CD8+ T cells in murine skin and heart allograft rejection across different
antigenic disparities Transplant Immunology 13: 297-304
Smith RM 2004 CMV prophylaxis: a useful step towards prevention of posttransplant diabetes? Diabetologia 47(9):1473-5
Smith RM, Gale EA. 2005 Survival of the fittest? Natural selection in islet
transplantation. Transplantation. 79:1301-3
Richards S, Parton L, LeClerc I, Rutter GA & Smith RM 2005 Overexpression of AMP-activated protein kinase impairs pancreatic b-cell function
in vivo. Journal of Endocrinology 187: 225-235
Ravanan R, Spiro J, Mathieson P, Smith RM 2007 Impact of diabetes on
haemoglobin levels in renal disease Diabetologia 50: 26-31
Cross SE, Richards SK, Clark A, Benest AV, Bates DO, Mathieson PW,
Johnson PRV, Harper SJ and Smith RM 2007 Vascular endothelial growth
factor as a survival factor for human islets: effect of immunosuppressive
drugs. Diabetologia 50:1423-32 Ravanan R, Wong SF, Morgan NG,
Mathieson PW, Smith RM 2007 Inhalation of glutamic acid decarboxylase
65-derived peptides can protect against recurrent autoimmune but not
alloimmune responses in the non-obese diabetic mouse Clinical and
Experimental Immunology 148:368-72
Laugharne M, Cross S, Richards S, Dawson C, Ilchyshyn L, Saleem M,
Mathieson P, Smith R 2007 Sirolimus Toxicity and Vascular Endothelial
Growth Factor Release from Islet and Renal Cell Lines. Transplantation
83:1635-1638
Thomas IJ, Petrich de Marquesini LG, Ravanan R, Smith RM, Guerder S,
Flavell RA, Wraith DC, Wen L and Wong FS 2007 CD86 has sustained
costimulatory effects on CD8 T cells. J. Immunol. 179:5936-5946.
Stewart H, Ravanan R, Smith R. 2007 In vivo models for the study of
transplantation tolerance. Methods in Molecular Biology 380:337-46.
Diraison F, Ravier MA, Richards SK, Smith RM, Shimano H, and Rutter GA
2008 SREBP1 is required for the induction by glucose of pancreatic β-cell
genes involved in glucose sensing Journal of Lipid Research 49:814-822.
Speight J, Reaney MD, Woodcock AJ, Smith RM, Shaw JA 2010 Patientreported outcomes following islet cell or pancreas transplantation (alone or
after-kidney) in Type 1 diabetes: a systematic review Diabetic Medicine
27:812-22
Smith R and Friend P 2010 Indications, patient evaluation and selection In
Pancreas, Islet and Stem cell transplantation for diabetes p51-62 Eds Hakim
NS, Stratta RJ, Gray D, Friend P and Colman A Oxford University Press
Chatzizacharias NA, Vaidya A, Sinha S, Smith R, Jones G, Sharples E,
Friend PJ. 2011 Renal function in type 1 diabetics one year after successful
pancreas transplantation. Clinical Transplantation, 25: E509–E515
Chatzizacharias NA, Vaidya A, Sinha S, Sharples E, Smith R, Jones G,
Brockmann J, Friend PJ. 2012 Risk analysis for deterioration of renal function
after pancreas alone transplant. Clinical Transplantation 26:387-92